Translator Disclaimer
25 April 2005 Preclinical evaluation of zinc phthalocyanine tetrasulfonate-based PDT
Author Affiliations +
Abstract
Photodynamic therapy (PDT) involves the light activation of a drug within a tumor causing selective tumor cell death. Unfortunately, some photosensitizing drugs have been associated with adverse reactions in veterinary patients. Zinc phthalocyanine tetrasulfonate (ZnPcS4) is a promising second-generation photosensitizer for use in veterinary medicine, however, it cannot be applied clinically until safety and efficacy data are available. ZnPcS4 was given to Swiss Webster mice to assess acute toxicity. Doses >100 mg/kg were associated with acute toxicity and mortality, and doses >100 mg/kg resulted in renal tubular nephrosis, suggesting that the minimum toxic dose is approximately 100 mg/kg. Based on these data, a Phase I clinical trial of ZnPcS4-based PDT in tumor-bearing dogs is underway, with ZnPcS4 doses up to 2 mg/kg producing no apparent toxicity. Tumor response has been observed after ZnPcS4-based PDT using doses as low as 0.25 mg/kg, suggesting that conventional phase I clinical trials may not be appropriate for PDT protocols.
© (2005) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Antonella Borgatti-Jeffreys, Stephen B. Hooser, Margaret A. Miller, Rose M. Thomas, Amalia deGortari, and Michael D. Lucroy D.V.M. "Preclinical evaluation of zinc phthalocyanine tetrasulfonate-based PDT", Proc. SPIE 5686, Photonic Therapeutics and Diagnostics, (25 April 2005); https://doi.org/10.1117/12.588378
PROCEEDINGS
7 PAGES


SHARE
Advertisement
Advertisement
RELATED CONTENT


Back to Top